| Authors: |
Zappacosta F; Discovery Analytical, Medicinal Science and Technology, GlaxoSmithKline, Collegeville, Pennsylvania, USA., Wagner CD; Discovery Analytical, Medicinal Science and Technology, GlaxoSmithKline, Collegeville, Pennsylvania, USA., Della Pietra A 3rd; Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania, USA., Gerhart SV; Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania, USA., Keenan K; Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania, USA., Korenchuck S; Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania, USA., Quinn CJ; Discovery Analytical, Medicinal Science and Technology, GlaxoSmithKline, Collegeville, Pennsylvania, USA., Barbash O; Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania, USA., McCabe MT; Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania, USA., Annan RS; Discovery Analytical, Medicinal Science and Technology, GlaxoSmithKline, Collegeville, Pennsylvania, USA. Electronic address: roland.s.annan@gsk.com. |